| Identification | Back Directory | [Name]
mumefural | [CAS]
222973-44-6 | [Synonyms]
mumefural
1,2,3-Propanetricarboxylicacid, 2-hydroxy-, 1-[(5-formyl-2-furanyl)methyl] ester | [Molecular Formula]
C12H12O9 | [MOL File]
222973-44-6.mol | [Molecular Weight]
300.22 |
| Hazard Information | Back Directory | [Uses]
Mumefural is a bioactive component of the processed fruit of Prunus mume Sieb. Mumefural inhibits platelet aggregation. Mumefural shows anti-thrombotic effects and ameliorates cognitive impairment[1][2]. | [Definition]
ChEBI: Mumefural is a carbonyl compound. | [in vivo]
Mumefural (0.1-10 mg/kg; i.p.; once) shows anti-thrombotic effects in rats[1].
Mumefural (20-80 mg/kg; oral; daily for 42 days) ameliorates cognitive impairment in chronic cerebral hypoperfusion via regulating the septohippocampal cholinergic system and neuroinflammation[2]. | Animal Model: | SD rats, FeCl3-induced arterial thrombosis model[1] | | Dosage: | 0.1, 1, or 10 mg/kg | | Administration: | Intraperitoneal injection, 30 min before 35% FeCl3 treatment | | Result: | Significantly improved blood flow by inhibiting occlusion and thrombus formation. Prevented collagen fiber damage in injured vessels and inhibited the expression of the platelet activation-related proteins P-selectin and E-selectin. Significantly reduced the increased inflammatory signal of nuclear factor (NF)-κB, toll-like receptor 4 (TLR4), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 in blood vessels. |
| Animal Model: | Male Wistar rats, Chronic cerebral hypoperfusion (CCH) model[2] | | Dosage: | 20, 40, or 80 mg/kg | | Administration: | Oral, once a day for 42 days | | Result: | Significantly improved cognitive impairment. Inhibited cholinergic system dysfunction, attenuated choline acetyltransferase-positive cholinergic neuron loss. Inhibited myelin basic protein degradation and increased the hippocampal expression of synaptic markers and cognition-related proteins. Reduced neuroinflammation, inhibited gliosis, and attenuated the activation of P2X7 receptor, TLR4/MyD88, NLRP3, and NF-κB. |
| Animal Model: | SD rats[1] | | Dosage: | 2 or 10 mg/kg | | Administration: | IV or PO (Pharmacokinetic Analysis) | | Result: | Plasma pharmacokinetic parameters of Mumefural in SD rats[1]
| T1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUC0-t (ng?h/mL) | F (%) | | IV (2 mg/kg) | 0.14±0.05 | 0.08±0 | 1894.54±580.66 | 564.73±178.35 | - | | PO (2 mg/kg) | 0.69±0.69 | 0.31±0.13 | 1731.61±290.64 | 1043.28±202.37 | 36.95±7.17 |
AUC(0–t): area under the curve from the time of dosing to infinity; Cmax: maximum concentration; F: bioavailability; T1/2: terminal half-life; Tmax: time of the maximum concentration; SD: standard deviation; F was calculated using the following formula
|
| [IC 50]
NF-κB; TLR4; P-selectin; E-selectin; TNF-α | [References]
[1] Bang J, et al. Mumefural Improves Blood Flow in a Rat Model of FeCl3-Induced Arterial Thrombosis. Nutrients. 2020 Dec 10;12(12):3795. DOI:10.3390/nu12123795
[2] Bang J, et al. Mumefural Ameliorates Cognitive Impairment in Chronic Cerebral Hypoperfusion via Regulating the Septohippocampal Cholinergic System and Neuroinflammation. Nutrients. 2019 Nov 13;11(11):2755. DOI:10.3390/nu11112755 |
|
|